Close Menu

NEW YORK (360Dx) – Pelago Bioscience today announced it has been granted SEK3.6 million ($429,000) to use its technology to identify new oncology biomarkers for treating childhood leukemia.

The Swedish firm will use its CETSA technology to profile the effects of a drug on up to 6,000 proteins from patient blood samples in order to identify biomarkers associated with best clinical outcomes for six commonly used cancer drugs, it said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.